These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21083127)

  • 1. Why I love metabolites in safety testing (MIST): a light-hearted historical perspective.
    Tonelli A
    Bioanalysis; 2009 Jul; 1(4):683-5. PubMed ID: 21083127
    [No Abstract]   [Full Text] [Related]  

  • 2. Historical perspectives.
    Florence AT
    Int J Pharm; 2005 Nov; 305(1-2):1. PubMed ID: 16198074
    [No Abstract]   [Full Text] [Related]  

  • 3. Overview of metabolite safety testing from an industry perspective.
    Anderson S; Knadler MP; Luffer-Atlas D
    Bioanalysis; 2010 Jul; 2(7):1249-61. PubMed ID: 21083238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolites in safety testing: "MIST" for the clinical pharmacologist.
    Frederick CB; Obach RS
    Clin Pharmacol Ther; 2010 Mar; 87(3):345-50. PubMed ID: 20107437
    [No Abstract]   [Full Text] [Related]  

  • 5. Issues in the safety testing of metabolites.
    Gross G; Wilson I
    Future Med Chem; 2009 Nov; 1(8):1381-90. PubMed ID: 21426053
    [No Abstract]   [Full Text] [Related]  

  • 6. Introduction: Human metabolites in safety testing (MIST) issue.
    Guengerich FP
    Chem Res Toxicol; 2009 Feb; 22(2):237-8. PubMed ID: 19216576
    [No Abstract]   [Full Text] [Related]  

  • 7. Historical development of pediatric pharmacology.
    Seyberth HW; Rane A; Schwab M
    Handb Exp Pharmacol; 2011; 205():v-vi. PubMed ID: 22046631
    [No Abstract]   [Full Text] [Related]  

  • 8. [Drug quality control--the contribution of pharmacy to drug safety. The historical development of the Working Group for Drug Control-Pharmaceutical Analysis of the German Pharmaceutical Society. 2].
    Göber B; Kny L; Langner A
    Pharm Unserer Zeit; 2000 Jul; 29(4):237-42. PubMed ID: 10969536
    [No Abstract]   [Full Text] [Related]  

  • 9. Looking back through the MIST: a perspective of evolving strategies and key focus areas for metabolite safety analysis.
    Nedderman AN; Wright P
    Bioanalysis; 2010 Jul; 2(7):1235-48. PubMed ID: 21083237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From history of pharmacy to pharmaceutical history.
    Watkins ES
    Pharm Hist; 2009; 51(1):3-13. PubMed ID: 20027914
    [No Abstract]   [Full Text] [Related]  

  • 11. [Status of side effects. 2. Adverse effects from a historical point of view. Classic examples].
    Lunde PK; Myhr K
    Tidsskr Nor Laegeforen; 1989 Nov; 109(31):3225-6. PubMed ID: 2688189
    [No Abstract]   [Full Text] [Related]  

  • 12. Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing.
    Smith DA; Obach RS
    Drug Metab Dispos; 2005 Oct; 33(10):1409-17. PubMed ID: 15985503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The historical role of gas chromatography in bioanalysis.
    Chamberlain J
    Bioanalysis; 2010 Feb; 2(2):167-9. PubMed ID: 21083297
    [No Abstract]   [Full Text] [Related]  

  • 14. Historical perspective on the development and evolution of bioanalytical guidance and technology.
    Shah VP; Bansal S
    Bioanalysis; 2011 Apr; 3(8):823-7. PubMed ID: 21510754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When authorship met authenticity.
    Johns A
    Nature; 2008 Feb; 451(7182):1058-9. PubMed ID: 18305531
    [No Abstract]   [Full Text] [Related]  

  • 16. NMR spectroscopy as a tool to close the gap on metabolite characterization under MIST.
    Caceres-Cortes J; Reily MD
    Bioanalysis; 2010 Jul; 2(7):1263-76. PubMed ID: 21083239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.
    Leclercq L; Cuyckens F; Mannens GS; de Vries R; Timmerman P; Evans DC
    Chem Res Toxicol; 2009 Feb; 22(2):280-93. PubMed ID: 19183054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A light-hearted look at a lion-hearted organ (or, a perspective from three standard deviations beyond the norm). Part 1 (of two parts).
    Loe MJ; Edwards WD
    Cardiovasc Pathol; 2004; 13(5):282-92. PubMed ID: 15358343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A light-hearted look at a lion-hearted organ (or, a perspective from three standard deviations beyond the norm) part 2 (of 2 parts).
    Loe MJ; Edwards WD
    Cardiovasc Pathol; 2004; 13(6):334-40. PubMed ID: 15556782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drugs and historical determinism].
    Baumann D; Friedrich C; Seidlein HJ
    Pharmazie; 1986 Nov; 41(11):806-11. PubMed ID: 3550822
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.